Business
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\n\nSubgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)\n\n\n\nThree independent long-term real-world analyses of JELMYTO® (mitomycin) for pyelocalyceal solution exploring its use in broad patient types and method of administration\n\n\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on investigational drug UGN-102 (mitomycin) and JELMYTO and will be presented at the American Urological Association (AUA) 2024 Annual Meeting being held in San Antonio, Texas from May 3 – 6.\n\n\n“We are proud that the AUA selected the ATLAS post-hoc analysis as a podium presentation,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “The results highlight UGN-102’s potential to help significantly advance treatment for patients with newly diagnosed and recurrent LG-IR-NMIBC, a highly prevalent and recurrent disease. Additionally, we are excited to see additional independent real-world evidence related to JELMYTO treatment of LG-UTUC patients in a diverse patient types.”\n\n\nKey details of UGN-102 and JELMYTO abstracts accepted by AUA:\n\n\n\n\nAbstract Title\n\n\n\n\n\n\nPresentation Details\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nResponse to Primary Chemoablation with UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial\n\n\n\n\n \n\n\n\n\n\n\nPodium Oral Presentation:\nAbstract ID 24-6641,\nSaturday, May 4,\n2:20-2:30 PM CDT,\nLocation 304A\n\n\n\n\n\n\nPresenter: Dr. William Huang\n\n\n\n\n\n\n\n\nLongitudinal Follow Up of Multicenter Study of UGN-101 for Upper Tract Urothelial Cancer\n\n\n\n\n\n\nPodium Oral Presentation:\nAbstract ID 24-7470,\nSunday, May 5,\n11:10-11:20 AM CDT,\nLocation 301A\n\n\n\n\n\n\nPresenter: Dr. Yair Lotan\n\n\n\n\n\n\n\n\nExploring Recurrence After Initial Response to UGN-101 Induction in Expanded Settings\n\n\n\n\n\n\nPodium Oral Presentation:\n\n\n\n\nAbstract ID 24-7534,\nSunday May 5,\n11:20-11:30 AM CDT,\nLocation 301A\n\n\n\n\n\n\nPresenter: Dr. Adam Feldman\n\n\n\n\n\n\n\n\nMitomycin-containing Reverse Thermal Gel UGN-101 for Upper Tract Urothelial Carcinoma: Retrograde Instillation...